RNA Immunotherapy for Solid Tumors: Mechanisms, Advances, and Clinical Implications

Abstract

RNA immunotherapy represents a rapidly expanding frontier in the treatment of solid tumors, leveraging advances in molecular biology, immunology, and nucleic acid technology to modulate the immune system against cancer. By harnessing the unique properties of RNA molecules, including mRNA vaccines and small interfering RNAs (siRNAs), this innovative therapeutic approach offers the potential for personalized, tumor-targeted, and immune-activating interventions. This review provides an evidence-based summary of RNA immunotherapy's mechanisms, clinical impact, and future directions, with a focus on its application to solid tumors, recent clinical trial data, guideline recommendations, and practical challenges in oncology care.

Introduction

The landscape of cancer immunotherapy has undergone a profound transformation in recent years, with RNA-based strategies emerging as powerful tools to stimulate anti-tumor immunity. Unlike traditional chemotherapeutics or monoclonal antibodies, RNA immunotherapies enable direct manipulation of cellular processes and immune responses at the molecular level. The clinical success of mRNA vaccines for infectious diseases has accelerated research into their application for oncology, particularly in the context of solid tumors, where immune evasion and heterogeneity present significant therapeutic barriers. This article thoroughly examines the current state of RNA immunotherapy for solid tumors, integrating mechanistic insights, clinical trial data, and expert recommendations for practicing oncologists.

Epidemiology / Disease Burden

Solid tumors, encompassing malignancies such as lung, breast, colorectal, prostate, and pancreatic cancers, account for the majority of cancer incidence and mortality worldwide. According to recent GLOBOCAN data, solid tumors contribute to over 80% of annual cancer-related deaths. Despite advances in surgery, radiotherapy, and systemic therapies, outcomes for patients with advanced-stage solid tumors remain poor, with five-year survival rates varying widely by tumor type and stage. The high global disease burden underscores the urgent need for innovative therapeutics capable of overcoming tumor resistance and immune suppression, driving the exploration of RNA-based immunotherapies.

Pathophysiology

Solid tumors develop through the accumulation of genetic and epigenetic alterations leading to uncontrolled cell proliferation, invasion, and metastatic dissemination. A hallmark of solid tumors is their ability to evade immune surveillance, mediated by immunosuppressive microenvironments, defective antigen presentation, and upregulation of immune checkpoints. RNA immunotherapies address these challenges by encoding tumor-associated antigens (TAAs) or immune modulators that can reprogram immune responses, enhance antigen presentation, and stimulate cytotoxic T lymphocyte (CTL) activity. The flexibility of RNA platforms allows for the rapid development of vaccines tailored to individual tumor profiles and neoantigens, facilitating personalized cancer immunotherapy.

Risk Factors

Risk factors for solid tumors are diverse, spanning genetic predisposition (e.g., BRCA mutations in breast and ovarian cancer), environmental exposures (e.g., tobacco, ultraviolet radiation), chronic infections (e.g., HPV in cervical cancer, HBV/HCV in hepatocellular carcinoma), lifestyle factors (obesity, diet), and age. These risk factors not only influence tumorigenesis but may also impact tumor immunogenicity and the responsiveness to immunotherapeutic interventions, including RNA-based modalities. Understanding patient-specific risk profiles is essential for optimizing immunotherapy selection and predicting clinical outcomes.

Clinical Features

The clinical presentation of solid tumors varies widely depending on the organ of origin, tumor size, and metastatic burden. Common symptoms include localized pain, mass effect, organ dysfunction, and systemic features such as weight loss or paraneoplastic syndromes. Importantly, many solid tumors remain asymptomatic until advanced stages, highlighting the need for effective systemic therapies capable of eliciting durable responses in metastatic disease. The heterogeneity of clinical features also poses challenges for the design and evaluation of immunotherapies in heterogeneous patient populations.

Diagnosis

Diagnosis of solid tumors relies on a combination of imaging (CT, MRI, PET), histopathological examination, and increasingly, molecular profiling. Molecular diagnostics, including next-generation sequencing, enable the identification of actionable mutations, neoantigens, and immune signatures that inform the selection of RNA immunotherapies. Liquid biopsies and tumor microenvironment analyses are emerging as valuable tools for monitoring treatment response and identifying biomarkers predictive of immunotherapy efficacy, such as tumor mutational burden (TMB) and PD-L1 expression.

Treatment & Management

Standard management of solid tumors typically involves multimodal approaches: surgical resection for localized disease, radiotherapy, and systemic therapies including cytotoxic chemotherapy, targeted agents, and immune checkpoint inhibitors. RNA immunotherapies are being incorporated into this paradigm as both standalone and combinatorial strategies. mRNA cancer vaccines encode TAAs or neoantigens, stimulating robust T cell responses, while siRNAs and microRNAs (miRNAs) can silence oncogenes or modulate immune pathways. Clinical trials have demonstrated the safety and immunogenicity of RNA vaccines in melanoma, non-small cell lung cancer (NSCLC), and other solid tumors, with ongoing studies investigating optimal dosing, delivery platforms (lipid nanoparticles, dendritic cell loading), and synergistic combinations with existing immunotherapies.

Recent Advances / Emerging Therapies

Recent advances in RNA immunotherapy include the development of personalized mRNA vaccines targeting patient-specific neoantigens, synthetic self-amplifying RNA (saRNA) constructs for enhanced antigen expression, and novel delivery technologies to improve stability and tumor targeting. Notable examples include BNT111 (BioNTech) in advanced melanoma and mRNA-4157 (Moderna) in combination with pembrolizumab for melanoma and other solid tumors, which have shown promising immunogenicity and early clinical efficacy. Additionally, siRNA-based therapeutics such as patisiran have paved the way for further research into gene-silencing approaches in oncology. The integration of next-generation sequencing and bioinformatics facilitates rapid antigen discovery and vaccine design, supporting the paradigm shift toward individualized immunotherapeutics.

Guideline Recommendations

While RNA immunotherapy for solid tumors remains investigational, leading oncology societies (e.g., ASCO, ESMO) recognize its potential and recommend consideration of clinical trial enrollment for eligible patients. Guidelines emphasize the importance of biomarker-driven patient selection, multidisciplinary care, and ongoing monitoring for immune-related adverse events (irAEs). As evidence accumulates, it is anticipated that future guidelines will incorporate RNA-based modalities into standard algorithms, particularly for tumors with high mutational burden or limited response to existing therapies.

Conclusion

RNA immunotherapy is at the vanguard of cancer treatment innovation, offering a versatile and potent strategy for mobilizing the immune system against solid tumors. By enabling personalized antigen targeting and immune modulation, RNA-based therapies have demonstrated promising safety and efficacy in early-phase clinical trials, with significant potential to improve outcomes in patients with advanced malignancies. Continued research, technological refinement, and integration into clinical practice will be critical for realizing the full therapeutic promise of RNA immunotherapy in solid tumors.